Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 960Glioblastoma 299Gliosarcoma 288Osteosarcoma 286Brain Neoplasms 195Dendritic Cell Sarcoma, Interdigitating 188Gastrointestinal Stromal Tumors 180Bone Neoplasms 172Lymphoma 161Central Nervous System Neoplasms 160Astrocytoma 155Sarcoma, Ewing 151Glioma 149Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Lymphoma, Non-Hodgkin 143Burkitt Lymphoma 139Neoplasms 137Recurrence 134Lymphoma, Large B-Cell, Diffuse 128Lymphoma, Follicular 128Rhabdomyosarcoma 126Neuroblastoma 126Hodgkin Disease 124Oligodendroglioma 123Breast Neoplasms 123Lymphoma, Mantle-Cell 117Leukemia, Myeloid, Acute 117Leukemia, Lymphocytic, Chronic, B-Cell 117Lymphoma, B-Cell, Marginal Zone 113Leukemia 111

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bladder Adenocarcinoma × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡